NCT01316835Unknown不适用
A Retrospective, Observational Study to Assess the Effectiveness of Glycemic Control of Diabetes in Real World After Sitagliptin Usage
Chang Gung Memorial Hospital1 个研究点 分布在 1 个国家目标入组 1,120 人开始时间: 2010年12月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,120
- 试验地点
- 1
研究概览
简要总结
This study will evaluate whether the addition of sitagliptin treatment provides additional decrease in HbA1C levels and increase in goal attainment in patients with inadequate glycemic control on their current oral anti-glycemic therapy in real world practice.
详细描述
To explore the change of glycemic control (HbA1c or FPG) before and after 24 weeks of Sitagliptin treatment in Type 2 Diabetic patients who have started Sitagliptin as add on therapy during the index period and received Sitagliptin continuously* for at least 24 weeks.
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects diagnosed of type 2 diabetes (ICD-9 code= 250.0; 250.1; 250.2; 250.3; 250.4; 250.5; 250.6) and have been followed up regularly in the study center who have started to receive Sitagliptin as an add-on treatment to their prior regimen during the index period
- •Subjects must be on a stable dose of all antidiabetic regimens, with stable dose defined as "at least 3 months with no therapy/dose change" prior to adding sitagliptin
- •Subjects in whose medical records a minimum core data set can be found.
排除标准
- •Subjects with type 1 DM
- •Subjects have been treated with insulin regularly
- •Subject with DM which results from other general diseases, e.g. surgery, pharmaceutical products, malnutrition, infections and other conditions
- •Subjects who participated in a clinical trial or other clinical study during the index period
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)Type 2 Diabetes MellitusNCT01076075Merck Sharp & Dohme LLC427
已完成
3 期
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)Type 2 DiabetesDiabetes MellitusNCT01485614Merck Sharp & Dohme LLC200
已完成
3 期
Effect of Januvia on Beta Cell Function in Patients With Diabetes MellitusDiabetes Mellitus Type 2NCT00425490Sheba Medical Center30
已完成
4 期
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac SurgeryHyperglycemiaNCT02556918Emory University202
已完成
4 期
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin TherapyDiabetesAtherosclerosisNCT01859793Medical College of Wisconsin38